Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Consilium Wealth Advisory LLC

Consilium Wealth Advisory LLC lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 33.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,773 shares of the medical research company's stock after acquiring an additional 1,203 shares during the period. Consilium Wealth Advisory LLC's holdings in Amgen were worth $1,487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in AMGN. Vista Investment Partners LLC purchased a new position in Amgen in the 1st quarter worth approximately $203,000. AA Financial Advisors LLC acquired a new stake in shares of Amgen in the first quarter valued at approximately $524,000. Inscription Capital LLC purchased a new position in Amgen during the first quarter worth approximately $348,000. Blackston Financial Advisory Group LLC boosted its stake in Amgen by 8.5% during the first quarter. Blackston Financial Advisory Group LLC now owns 1,148 shares of the medical research company's stock worth $358,000 after buying an additional 90 shares during the last quarter. Finally, Mountain Pacific Investment Advisers LLC grew its holdings in Amgen by 1.7% in the 1st quarter. Mountain Pacific Investment Advisers LLC now owns 6,434 shares of the medical research company's stock valued at $2,004,000 after buying an additional 110 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Amgen stock traded down $0.42 during midday trading on Wednesday, reaching $289.63. 2,025,171 shares of the company were exchanged, compared to its average volume of 2,819,601. The firm's 50-day simple moving average is $281.62 and its 200-day simple moving average is $285.78. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market capitalization of $155.74 billion, a price-to-earnings ratio of 26.43, a P/E/G ratio of 2.62 and a beta of 0.51. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the previous year, the firm posted $3.96 EPS. Amgen's revenue was up 9.4% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.76% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AMGN. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Johnson Rice set a $294.00 price target on Amgen in a research note on Wednesday, March 5th. Royal Bank Of Canada lowered their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Guggenheim initiated coverage on shares of Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Finally, UBS Group reaffirmed a "neutral" rating and set a $315.00 target price (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.